To the best of our knowledge, this is the first study to demonstrate the application of in vivo genome editing for treatment of diseases not associated with specific genetic lesions or aberrations
Emerging technologiesremote care, robotics, advances in biomedical science, and especially artificial intelligenceare accelerating reductions in the resources needed to deliver effective treatment
see section by Popa and Hallett)
The TRIUMPH-4 trial reported that cardiovascular risk markers were reduced, including non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein
Los agonistas del receptor GLP-1 (pptido similar al glucagn tipo 1), como semaglutida, dulaglutida y liraglutida, actan imitando una hormona intestinal natural que regula el azcar en sangre y el apetito
Any dose adjustments need to be undertaken on an individualised basis considering individual patient considerations, HbA1c target, hypoglycaemic awareness and medication regimen[511]
